2018 Section 5 - Rhinology and Allergic Disorders

Group Outcomes Conclusions

n = 8, placebo Sx, NPS (TPS) 1 mg/kg arm had more responders improving NPS No significant change in CT score placebo Sx, NPS (TPS), CT (% improvement)

Significant improvement in all 3 outcomes

Significant improvement in CT score

No significant improvement in Sx or NPS

Significant improvement in all outcomes

Significant improvement in NPS No significant improvement in CT score

All patients with severe asthma n = 19, wt and IgE based dose n/a NPS (TPS) Significant decrease in NPS and also intranasal steroid use All patients with severe atopic asthma n = 6 n/a Sx (SNOT-20, AQLQ), CT (Lund- Mackay)

Significant decrease in Sx and CT scores

20, SF-36), NPS

(endoscopic polyp grade, 4 pt), CT

(% opacification)

CT (Lund-Mackay)

polyp grade), CT (Lund-Mackay)

NPS (endoscopic

Control

Historically matched

controls

n = 7 placebo Sx (UPSIT, SNOT-

n = 8, placebo Sx (SF-36), NPS (TPS),

n = 8 at 1 mg/kg

n = 20 at 750 mg n = 10, n = 7 at 0.016 mg/ kg per IU total serum IgE/mL

n = 16 wt and IgE based dose

(max 350 mg)

Disease Asthma Treatment Group polyposis or

n = 8 at 3 mg/kg;

n = 4 (150-375 mg) n = 4,

7/8 in 1 mg/kg arm,

6/8 control asthma hx

control asthma hx

5/7 tx and 3/7 control asthma inhaler use reported

comorbid asthma

All patients with atopic asthma

5/8 in 3 mg/kg arm,

10/20 Tx and 3/10

All patients with

polyposis or

polyposis and

Sinonasal

recurrent

after surgery Severe

recurrent

after surgery Severe

recurrent

after surgery

CRSwNP and asthma

CRSwNP after surgery and asthma

Asthma with CRSwNP

ECRS with asthma

Severe

(anti-IL5)

(anti-IL5)

(anti-IgE)

(anti-IgE)

(anti-IgE)

(anti-IgE)

(anti-IgE)

4 Omalizumab

Tajiri, 2013 30 4 Omalizumab

Table 1.  Summary of Included Articles. Lead Author, Year LOE Therapy Gevaert, 2006 27 1b Reslizumab Gevaert, 2011 8

1b Mepolizumab

Pinto, 2010 13 1b Omalizumab

1b Omalizumab

Penn, 2007 29 3b Omalizumab

Gevaert, 2013 28

Vennera, 2011 31

Abbreviations: AQLQ, Asthma Quality of Life Questionnaire; CRSwNP, chronic rhinosinusitis with nasal polyposis; CT, computed tomography; ECRS, eosinophilic chronic rhinosinusitis; NPS, nasal polyp score; RCT, randomized controlled trial; SF-36, 36-Item Short Form Survey; SNOT-20, Sinonasal Outcome Test 20; Sx, symptoms; TPS, total polyp score; UPSIT, University of Pennsylvania Smell Identification Test.

202